Performance of Elastic Liposomes for Topical Treatment of Cutaneous Leishmaniasis

Rossi-Bergmann, Bartira; Falcão, Camila Alves Bandeira; Zanchetta, Beatriz; Bentley, Maria Vitória Lopes Badra; Santana, Maria Helena Andrade

doi:10.1007/978-3-642-19792-5_9

Cited by 8 publications

(9 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interest in designing nanomedicines for CL has grown over the years, as seen by the steady increase in scientific publications. Several nanosystems, such as liposomes [10][11][12][13][14][15][16][17][18][19][20], solid lipid nanoparticles [21,22], lipid complexes [23,24], lipid-core nanocapsules [25], polymeric particles [26][27][28][29][30][31], inorganic nanoparticle [32][33][34][35], cyclodextrins complexes [36,37], and drug nanoparticles [38] have been tested in vivo by different routes in experimental mouse and hamster models to improve CL treatment as summarized in Table 1 amphotericin B has been approved for human leishmaniasis so far, but that is restricted to VL and the more severe mucosal form of CL. Additional studies and clinical trials are needed to validate the potential of those experimental nanomedicines in human CL.…”

Section: Leishmaniases As Re-emerging Diseases 182mentioning

confidence: 99%

“…In addition, the CH8 molecule exhibits physicochemical characteristics favorable to encapsulation with high efficiency in different nanosystems such as liposomes and polymeric particles. Indeed, CH8 loading into cationic liposomes interferes with the lipid structure rendering it more elastic, enhancing formulation permeation through the skin and increasing CH8 topical efficacy in L. amazonensis murine model [16].…”

Section: Topical Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Nanomedicines for Cutaneous Leishmaniasis

Sousa-Batista¹,

Rossi-Bergmann²

2018

Leishmaniases as Re-Emerging Diseases

Self Cite

View full text Add to dashboard Cite

Leishmaniasis is a vector-borne disease caused by Leishmania parasites, which cause a range of clinical manifestations in man. These are didactically classified into cutaneous leishmaniasis (CL), the most common form of the disease, and visceral leishmaniasis (VL), the life-threatening form. There are so far no vaccines approved for humans. Conventional drugs pose limitations ranging from low efficacy and high cost to systemic toxicity. Low efficacy derives in part from difficult drug access to the parasites, which rides themselves inside macrophage phagosomes. This prompts to high dosage, with consequent increased toxicity. Difficult intracellular drug access can be overcome with nanomedicines such as biocompatible lipid and polymeric nanoparticles that can be phagocytosed by the infected macrophages. Besides cell membranes, appropriate drug nanostructuring may allow tissue barrier penetration and drug administration through higher compliance routes such as skin and intestine, in contrast to the usual intravenous and intramuscular routes. In general, CL and VL are both treated with toxic systemic injections, disregard of disease severity. This chapter will review and discuss studies with nanomedicines that have reached the market such as liposomal amphotericin B for intravenous administration, and innovative preclinical studies aiming at developing effective cutaneous and oral drugs with focus on CL.

show abstract

Section: Leishmaniases As Re-emerging Diseases 182mentioning

confidence: 99%

Section: Topical Treatmentmentioning

confidence: 99%

Nanomedicines for Cutaneous Leishmaniasis

Sousa-Batista¹,

Rossi-Bergmann²

2018

Leishmaniases as Re-Emerging Diseases

Self Cite

View full text Add to dashboard Cite

show abstract

“…Recently, Rossi-Bergmann et al 16 investigated the incorporation of synthetic chalcones in the bilayer of small conventional unilamellar liposomes, and demonstrated that disturbances in the bilayer structure result in the formation of deformable liposomes with enhanced epidermal penetration, when compared with pegylated liposomes.…”

Section: Mattos Et Almentioning

confidence: 99%

“…16,44 The results show that, by combining soybean lecithin and polysorbate 20, a larger SC retention in the dermis was obtained. This may be attributed to the affinity of lecithin for cellular membranes, and to the ability of polysorbate 20 to form micelles in aqueous medium that extract lipids from the skin.…”

mentioning

confidence: 97%

Nanoemulsions containing a synthetic chalcone as an alternative for treating cutaneous leshmaniasis: optimization using a full factorial design

Mattos¹,

Argenta²,

Melchiades³

et al. 2015

IJN

View full text Add to dashboard Cite

Nanoemulsions are drug delivery systems that may increase the penetration of lipophilic compounds through the skin, enhancing their topical effect. Chalcones are compounds of low water solubility that have been described as promising molecules for the treatment of cutaneous leishmaniasis (CL). In this context, the aim of this work was to optimize the development of a nanoemulsion containing a synthetic chalcone for CL treatment using a 2 2 full factorial design. The formulations were prepared by spontaneous emulsification and the experimental design studied the influence of two independent variables (type of surfactant – soybean lecithin or sorbitan monooleate and type of co-surfactants – polysorbate 20 or polysorbate 80) on the physicochemical characteristics of the nanoemulsions, as well as on the skin permeation/retention of the synthetic chalcone in porcine skin. In order to evaluate the stability of the systems, the antileishmanial assay was performed against Leishmania amazonensis 24 hours and 60 days after the preparation of the nanoemulsions. The formulation composed of soybean lecithin and polysorbate 20 presented suitable physicochemical characteristics (droplet size 171.9 nm; polydispersity index 0.14; zeta potential −39.43 mV; pH 5.16; and viscosity 2.00 cP), drug content (91.09%) and the highest retention in dermis (3.03 µg·g −1 ) – the main response of interest – confirmed by confocal microscopy. This formulation also presented better stability of leishmanicidal activity in vitro against L . amazonensis amastigote forms (half maximal inhibitory concentration value 0.32±0.05 µM), which confirmed the potential of the nanoemulsion soybean lecithin and polysorbate 20 for CL treatment.

show abstract

“…The development of topical formulations could be an alternative method for the treatment of CL. Although the transdermal transport of drugs has many advantages over other routes of administration, there are still problems that need to be investigated, such as low penetration of most compounds through the human skin (Rossi-Bergmann et al 2011). The aim of this study was to investigate the effects of topical treatment with formulations containing pentamidine isethionate/PI (Pentacarinat®/Sanofi) in experimentally induced leishmanasis in Golden hamsters (Mesocricetus auratus) infected with Leishmania (Leishmania) amazonensis.…”

Section: Introductionmentioning

confidence: 99%

Topical treatment of experimental cutaneous leishmaniasis in golden hamster (Mesocricetus auratus) with formulations containing pentamidine

et al. 2017

View full text Add to dashboard Cite

Current treatment of cutaneous leishmaniasis (CL) relies mainly on pentavalent antimonials salts and second-line drugs include pentamidine and amphotericin B, but these therapies have side effects and require parenteral administration. The aim of this work was to evaluate the topical formulations containing pentamidine isethionate (PI) in the experimental treatment of cutaneous leishmaniasis (CL). Golden hamsters (Mesocricetus auratus) were infected in the nose with Leishmania (Leishmania) amazonensis. Six treatment groups received different topical treatments of anhydrous or hydrating emulsions, for a maximum of 10 days, with an application of 50 mg day -1. After treatment tissue samples of lesions were evaluated by histology, transmission electron microscopy and biopsy cultivation. Compared with untreated group, topical treatment with hydrating emulsion with 10% PI and usnic acid (ACE5AU) showed significantly decrease in volume lesion (P= 0.028) on 20 th day after the end of the treatment with reduction of 27.37%. Topical treatment with anhydrous emulsion with 10% PI and usnic acid (ACPU) reduces parasite burden in Golden hamsters. This study demonstrated the potential of topical treatment to reduce the number of parasites that could be combined with others drugs and to have a faster and more effective treatment of cutaneous leishmaniasis.

show abstract

Performance of Elastic Liposomes for Topical Treatment of Cutaneous Leishmaniasis

Cited by 8 publications

References 30 publications

Nanomedicines for Cutaneous Leishmaniasis

Nanomedicines for Cutaneous Leishmaniasis

Nanoemulsions containing a synthetic chalcone as an alternative for treating cutaneous leshmaniasis: optimization using a full factorial design

Topical treatment of experimental cutaneous leishmaniasis in golden hamster (Mesocricetus auratus) with formulations containing pentamidine

Contact Info

Product

Resources

About